To identify mTORC2-regulated molecules potentially implicated in the response of melanoma cells to targeted therapy, we have undertaken an unbiased proteomic approach to compare differentially expressed proteins between RICTOR-proficient and -deficient M14 and A375 cells under basal conditions. This evidence concerns the gene RICTOR and melanoma.